reports
Lifecore Biomedical to be Added to Nasdaq Biotech Index
Lifecore Biomedical to be Added to Nasdaq Biotech Index CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025. The Nasdaq Biotechnology Index ...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Larg...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement wit...
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthca...
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, includin...
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Jefferies 2025 Global Healthcare Conference – London Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and Lifecore management will parti...
Lifecore Biomedical Reports Financial Results for the Three Months End...
Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development an...
Lifecore Biomedical to Report Financial Results for the Three Months E...
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 Webcast Scheduled for Thursday, November 6 at 4:30 p.m. Eastern CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team ...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner b...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manuf...
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-...
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical custom...
Lifecore Biomedical to Participate at Upcoming Industry Conferences an...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company’s activities at these events are as follows: 15th Annual Partnership Opportunities in Drug Development (PODD)Conference Dates/Location: October 27-28, 2025, in Boston, MADetails: Ryan Swanson, Ph.D., Lifecore’s director of pro...
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newly hired em...
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Cont...
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 24th Annual Contract Pharma Contracting and Outsourcing Conference. Recognized as one of the top annual events for pharmaceutical outsourcing and contract manufacturing, the Contract Pharma conference will take place September 18-19, 2025, in New Brun...
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Morgan Stanley 23rd Annual Global Healthcare ConferenceDetails: Lifecore management will participate in a fireside chat and in investor meetingsConference Dates: September 8-10, 2025Fireside...
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financ...
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update -- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, In...
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Fina...
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025 Webcast Scheduled for Thursday, August 7 at 4:30 p.m. Eastern CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and fiscal year 2025 on Thursday, August 7, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast ...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., July 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on July 11, 2025, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate of 6,338 shares of its common stock and stock options for an aggregate of 29,575 shares of common sto...
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Sup...
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer Represents Continuation of Long-Running Partnership Focused on Supporting Advancement of Novel Ophthalmic Therapeutic Toward Commercialization CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer. This represents the latest agreem...
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Mill...
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach CHASKA, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has received the remaining $10 million in proceeds from the previously disclosed sale of its excess high-speed, multi-purpose 10-head isolator filler. The buyer elected to complete the full paymen...
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise as Leader of Lifecore’s Sales Organization Focused on Executing Three-Pronged Growth Strategy CHASKA, Minn., May 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has appointed Mark DaFonsec...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TITN TITAN MACHINERY
RCKY ROCKY BRANDS
LNDC LANDEC CORP.
EXAS EXACT SCIENCES CORPORATION
CRK COMSTOCK RESOURCES INC.
BEN FRANKLIN RESOURCES INC.
ATI ALLEGHENY TECHNOLOGIES INCORPORATED
BJRI BJ'S RESTAURANTS INC.
AVH AVITA MEDICAL CDI
ATEC ALPHATEC HOLDINGS INC.
WHG WESTWOOD HOLDINGS GROUP INC.
FLGT FULGENT GENETICS
IRTC IRHYTHM TECHNOLOGIES INC.
LAUR LAUREATE EDUCATION INC. CLASS A
ATGE ADTALEM GLOBAL EDUCATION INC.
OCBI ORANGE COUNTY BANCORP
ATOM ATOMERA
FULC FULCRUM THERAPEUTICS
IESC IES HOLDINGS INC.
ADPT ADAPTIVE BIOTECHNOLOGIES
PRDO PERDOCEO EDUCATION CORP
HIMS HIMS AND HERS HEALTH INC (A)
ACHR ARCHER AVIATION INC
ASTS AST SPACEMOBILE INC
RGTI RIGETTI COMPUTING INC
SKWD SKYWARD SPECIALTY INS GROUP INC
ASPI ASP ISOTOPES INC
BTSG BRIGHTSPRING HEALTH SERVICES INC.
DAVE DAVE INC
ASMB ASSEMBLY BIOSCIENCES INC
AEVA AEVA TECHNOLOGIES INC.
BKTI BK TECHNOLOGIES CORP
ALMU AELUMA INC
ACOG ALPHA COGNITION INC
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conferen...
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference. Billed as a premiere partnering event for the biopharma outsourcing industry, CDMO Live will take place May 7-8, 2025, in Rotterdam, Netherlands. During the conference, Jackie Klecker, Lifecore’s executive vice president, quality and development ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.